Lexicon Pharmaceuticals names Dr. Pablo Lapuerta CMO

Tuesday, March 29, 2011 12:15 PM

Lexicon Pharmaceuticals has named Pablo Lapuerta, M.D., chief medical officer. He will be responsible for directing clinical development of Lexicon's drug candidates from phase II proof-of-concept through phase III and approval.

Dr. Lapuerta has 15 years of pharmaceutical industry experience including leadership roles in drug development, global medical affairs and outcomes research strategy across multiple therapeutic areas. Most recently, Lapuerta served as vice president at Bristol-Myers Squibb, where he was responsible for global development of an Alzheimer's disease drug candidate.

Share:          
CWWeekly

March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs